Cannabichromene has been hypothesized to affect THC psychoactivity, though in vivo effects have not been demonstrated.[5] CBC acts on the
TRPV1 and
TRPA1 receptors, interfering with their ability to break down endocannabinoids (chemicals such as
anandamide and
2-AG that the body creates naturally).[6][unreliable source?] CBC has shown antitumor effects in breast cancer xenoplants in mice.[7] It also has
anticonvulsant activity in a
mouse model.[8]
In vitro, CBC binds weakly to
CB1 and
CB2 with binding affinities of 713 nM and 256 nM, respectively, which are significantly lower than that for
THC with 35 nM at CB1.[9][10] acting as an agonist for
cAMP stimulation and an antagonist at
beta-arrestin.[9] Additionally, CBC is an agonist of
TRPA1, and less potently
TRPV3 and
TRPV4.[3] CBC has two
stereoisomers.
References
^"Cannabichromene". PubChem. National Center for Biotechnology Information. 16 February 2019. Retrieved 12 February 2019.
^Ilan AB, Gevins A, Coleman M, ElSohly MA, de Wit H (September 2005). "Neurophysiological and subjective profile of marijuana with varying concentrations of cannabinoids". Behavioural Pharmacology. 16 (5–6): 487–96.
doi:
10.1097/00008877-200509000-00023.
PMID16148455.
S2CID827221.
^Ligresti, A.; Moriello, A. S.; Starowicz, K.; Matias, I.; Pisanti, S.; De Petrocellis, L.; Laezza, C.; Portella, G.; Bifulco, M.; Di Marzo, V. (2006-09-01). "Antitumor Activity of Plant Cannabinoids with Emphasis on the Effect of Cannabidiol on Human Breast Carcinoma | Journal of Pharmacology and Experimental Therapeutics". Journal of Pharmacology and Experimental Therapeutics. 318 (3): 1375–1387.
doi:
10.1124/jpet.106.105247.
PMID16728591.
S2CID1341744.
^Anderson LL, Ametovski A, Lin Luo J, Everett-Morgan D, McGregor IS, Banister SD, Arnold JC. Cannabichromene, Related Phytocannabinoids, and 5-Fluoro-cannabichromene Have Anticonvulsant Properties in a Mouse Model of Dravet Syndrome. ACS Chem Neurosci. 2021 Jan 20;12(2):330-339.
doi:
10.1021/acschemneuro.0c00677PMID33395525
Cannabichromene has been hypothesized to affect THC psychoactivity, though in vivo effects have not been demonstrated.[5] CBC acts on the
TRPV1 and
TRPA1 receptors, interfering with their ability to break down endocannabinoids (chemicals such as
anandamide and
2-AG that the body creates naturally).[6][unreliable source?] CBC has shown antitumor effects in breast cancer xenoplants in mice.[7] It also has
anticonvulsant activity in a
mouse model.[8]
In vitro, CBC binds weakly to
CB1 and
CB2 with binding affinities of 713 nM and 256 nM, respectively, which are significantly lower than that for
THC with 35 nM at CB1.[9][10] acting as an agonist for
cAMP stimulation and an antagonist at
beta-arrestin.[9] Additionally, CBC is an agonist of
TRPA1, and less potently
TRPV3 and
TRPV4.[3] CBC has two
stereoisomers.
References
^"Cannabichromene". PubChem. National Center for Biotechnology Information. 16 February 2019. Retrieved 12 February 2019.
^Ilan AB, Gevins A, Coleman M, ElSohly MA, de Wit H (September 2005). "Neurophysiological and subjective profile of marijuana with varying concentrations of cannabinoids". Behavioural Pharmacology. 16 (5–6): 487–96.
doi:
10.1097/00008877-200509000-00023.
PMID16148455.
S2CID827221.
^Ligresti, A.; Moriello, A. S.; Starowicz, K.; Matias, I.; Pisanti, S.; De Petrocellis, L.; Laezza, C.; Portella, G.; Bifulco, M.; Di Marzo, V. (2006-09-01). "Antitumor Activity of Plant Cannabinoids with Emphasis on the Effect of Cannabidiol on Human Breast Carcinoma | Journal of Pharmacology and Experimental Therapeutics". Journal of Pharmacology and Experimental Therapeutics. 318 (3): 1375–1387.
doi:
10.1124/jpet.106.105247.
PMID16728591.
S2CID1341744.
^Anderson LL, Ametovski A, Lin Luo J, Everett-Morgan D, McGregor IS, Banister SD, Arnold JC. Cannabichromene, Related Phytocannabinoids, and 5-Fluoro-cannabichromene Have Anticonvulsant Properties in a Mouse Model of Dravet Syndrome. ACS Chem Neurosci. 2021 Jan 20;12(2):330-339.
doi:
10.1021/acschemneuro.0c00677PMID33395525